«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

26卷

期数:

2020年03期

页码:

280-283

栏目:

技术与方法

出版日期:

2020-06-10

文章信息/Info

Title:

Study on compatible stability of ambroxol hydrochloride injection mixed with total parenteral nutrition

文章编号:

1006-8147(2020)03-0280-04

作者:

金津; 张文军; 袁恒杰

（天津医科大学总医院药剂科，天津 300052）

Author(s):

JIN Jin;  ZHANG Wen-jun;  YUAN Heng-jie

（Department of Pharmacy，General Hospital，Tianjin Medical University, Tianjin 300052, China)

关键词:

盐酸氨溴索; 全肠外营养液; 配伍; 稳定性

Keywords:

ambroxol hydrochloride; total parenteral nutrition; compatibility; stability

分类号:

R974+.1

DOI:

-

文献标志码:

A

摘要:

目的：考察盐酸氨溴索注射液与全肠外营养液的配伍稳定性。方法：按照无菌操作规程配制盐酸氨溴索注射液与全肠外营养液的配伍液后，考察其在室温下放置0、2、4、6、8、10、24 h后的微生物限度、外观，同时采用高效液相色谱法测定各时间点盐酸氨溴索的含量。结果： 24 h内配伍液无菌落发育，外观无显著性变化，且盐酸氨溴索在全肠外营养液中的含量也未发生变化。结论： 24 h内室温条件下盐酸氨溴索注射液在全肠外营养液中稳定。

Abstract:

Objective: To investigate the compatible stability of ambroxol hydrochloride injection mixed with total parenteral nutrition(TPN). Methods：Ambroxol hydrochloride injection was mixed with TPN according to sterile operation procedure. The microbial limit and appearance at room temperature were investigated at 0，2，4，6，8，10 and 24 h. The content of ambroxol hydrochloride was determined by HPLC. Results：Within 24 h, no bacterial colony was found in the mixture. There was no significant change in the appearance. No change was observed in the content of ambroxol hydrochloride in TPN. Conclusion：At room temperature, ambroxol hydrochloride in TPN is stable within 24 h．

参考文献/References:

[1] Jahnz-Rozyk K, Kucharczyk A, Chcialowski A, et al. The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients[J]. Pol Merkur Lekarski, 2001, 11（63）:239
[2] 李月清. 盐酸氨溴索的药理作用和临床分析[J].亚太传统医药,2009, 5（12）:102
[3] 孙雪芹, 刘斌, 张恩伟.盐酸氨溴索注射液治疗呼吸系统疾病疗效观察[J].中国社区医师, 2016, 32（35）:55
[4] Chlubek D, Zawierta J, Olszewska M, et al. Effect of ambroxol on lipid peroxidation in homogenates of the human placenta[J]. Ginekol Pol, 2001, 72（10）:804
[5] Hull J D, Lyon R A. In vitro pharmacology of ambroxol: Potential serotonergic sites of action[J]. Life Sci, 2018,197:67
[6] 蔡海彬, 刘国雄, 谢坚, 等. 盐酸氨溴索治疗慢性阻塞性肺疾病合并肺部感染的疗效观察[J]. 西北药学杂志, 2018, 33（1）:113
[7] 谢智锋.盐酸氨溴索辅助治疗支气管肺炎的疗效观察[J].临床合理用药杂志, 2015, 8（18）:43
[8] 刘艳强. 盐酸氨溴索辅助治疗支气管肺炎疗效观察[J].北方药学, 2013（11）:156
[9] 叶宏财, 刘阿仲. 盐酸氨溴索治疗支气管肺炎的临床分析[J].吉林医学, 2011, 32（35）:7490
[10] 梁旭满, 黄干. 慢阻肺合并肺部感染患者应用盐酸氨溴索和对症治疗的疗效观察[J]. 中国医学创新, 2015, 12（32）:19
[11] Malerba M, Ponticiello A, Radaeli A, et al. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study （the AMETHIST Trial）[J]. Pulm Pharmacol Ther, 2004, 17（1）:27
[12] Cazan D, Klimek L, Sperl A, et al. Safety of ambroxol in the treatment of airway diseases in adult patients[J]. Expert Opin Drug Saf, 2018, 17（12）:1211
[13] 王电军, 尹邦良, 喻风雷.盐酸氨溴索在体外循环肺损伤中的保护作用[J].中国现代医学杂志, 2003, 13（6）:17
[14] 邝土光,张洪玉,庞宝森,等.氨溴索弱化机体氧化/抗氧化失衡的实验与临床观察[J]. 中华医学杂志, 2001（8）:62
[15] Zhang B, Liu Y. Prophylaxis against ventilator-induced lung injury by Ambroxol[J]. Zhonghua Yi Xue Za Zhi, 2000, 80（1）:51
[16] 闫辉, 张敬晶.盐酸氨溴索临床研究进展[J]. 现代中西医结合杂志, 2011, 20（22）:2856
[17] Severina I S, Bussygina O G, Pyatakova N V, et al. Ambroxol as an inhibitor of nitric oxide-dependent activation of soluble guanylate cyclase[J]. Eur J Pharmacol, 2000, 407（1/2）:61
[18] Deretic V, Timmins G S. Enhancement of lung levels of antibiotics by ambroxol and bromhexine[J]. Expert Opin Drug Metab Toxicol, 2019,15（3）:213
[19] 高声传, 李杨. 不同处方全肠外营养液的稳定性考察[J]. 中国药房,2016,27（8）:1055
[20] 国家药典委员会. 中华人民共和国药典:四部[S]. 2015年版. 北京:中国医药科技出版社, 2015: 4-115

相似文献/References:

备注/Memo

备注/Memo:

作者简介 金津（1986-），女，主管药师，硕士在读，研究方向：药理学、临床药学；通信作者：袁恒杰， E-mail：hengjieyuan@163.com。

常用功能

更新日期/Last Update: 2020-06-13